KONINKLIJKE PHILIPS (PHG) Stock: Buy, Sell, or Hold?
PHG - KONINKLIJKE PHILIPS N.V.
$23.90
0.09 (0.36%)
▲
5d:
-4.27%
30d:
-9.39%
90d:
-15.15%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When PHG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PHG shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PHG shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$35.65
Based on 6.0% avg growth
INTRINSIC VALUE TODAY
$22.14
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHG is currently trading at $23.89, which is considered oversold relative to its 30-day fair value range of $24.43 to $26.47. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.5) compared to its historical average (14.0). Remarkably, the market is currently pricing in an annual earnings decline of 3.8% over the next few years. This pessimistic expectation contrasts with the company's recent 61.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHG is in a downtrend. The price is currently testing key support at $23.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $32.21 (+35.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHG is in a downtrend. The price is currently testing key support at $23.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $32.21 (+35.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$24.43 -
$26.47
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.3% below Wall St target ($32.21)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$24.43 -
$26.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$23.70
Resistance Level
$25.22
Current Trend
Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.51
Wall Street Target
$32.21
(+35.3%)
Revenue Growth (YoY)
0.5%
Earnings Growth (YoY)
61.4%
Profit Margin
6.3%
Valuation Discount vs History
-3.8% cheaper
PE vs Historical
12.5 vs 14.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.8%
(market-implied from PE analysis)
1-Year Target
$22.91
(-4%)
2-Year Target
$22.03
(-8%)
3-Year Target
$21.20
(-11%)
3-Yr Target (if PE normalizes)
(PE: 13→14)
$23.73
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 8.0%)
$48.91
(+105%)
Base:
(SPY PE: 12.5, Growth: 8.0%)
$29.99
(+26%)
Bear:
(PE: 10.6, Growth: 8.0%)
$25.49
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 18.79 | Current EPS (TTM): $1.30
Bull Case
$39.35
(+65%)
Analyst growth 46.4%, PE expands to 20.7
Base Case
$35.77
(+50%)
Market implied 46.4%, PE stable at 18.8
Bear Case
$16.61
(-30%)
Severe decline -20.0%, PE contracts to 16.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.5 to 14.0
Stabilization Target:
$26.65
(+11.9%)
PE Expansion Potential:
+11.9%
Share & Embed Analysis
Last updated: October 02, 2026 10:22 AM ET
Data refreshes hourly during market hours. Next update: 11:22 AM
Data refreshes hourly during market hours. Next update: 11:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 44 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$108 | 50 HOLD |
